Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will report its Q2 2022 financial results and provide a business update on August 4, 2022, after market close. A conference call will follow at 5:00 pm ET. The call can be accessed via phone or streamed online through the company's website. A replay will be available for 30 days post-call. Theravance is focused on delivering innovative medicines, including its FDA-approved YUPELRI® for COPD management.

Positive

• Theravance has an FDA-approved product (YUPELRI®) addressing COPD.
• Upcoming Q2 2022 financial results may provide insights into future growth.

Negative

• None.

DUBLIN, July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Conference Call Information

To participate in the live call by telephone, please dial (800) 225-9448 from the US or (203) 518-9708 for international callers, using the conference code TBPHQ222. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Presentations and Events.

A replay of the conference call will be available on Theravance Biopharma's website for 30 days through September 3, 2022. An audio replay will also be available through 11:59 pm ET on August 11, 2022 by dialing (888) 219-1261 from the US, or (402) 220-4941 for international callers.

About Theravance Biopharma

Theravance Biopharma, Inc.'s overarching purpose and goal as a biopharmaceutical company is focused on delivering Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant unmet patient needs. For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact: Gail B. Cohen
Corporate Communications / 917-214-6603

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-second-quarter-2022-financial-results-on-august-4-2022-301595049.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma report its Q2 2022 financial results?

Theravance Biopharma will report its Q2 2022 financial results on August 4, 2022.

What time is the conference call for Theravance Biopharma's Q2 results?

The conference call will take place at 5:00 pm ET on August 4, 2022.

How can I listen to the Theravance Biopharma conference call?

The conference call can be accessed by phone or streamed live on their website.

What is YUPELRI® and its significance for Theravance Biopharma?

YUPELRI® is Theravance's FDA-approved inhalation solution for COPD maintenance treatment.

Is there a replay available for the Theravance Biopharma conference call?

Yes, a replay of the conference call will be available for 30 days after the event.